Protein kinase CK2 inhibition as a pharmacological strategy.

Casein Kinase II / antagonists & inhibitors Drug Delivery Systems Humans Neoplasm Proteins / antagonists & inhibitors Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use
CK-II CK2 CX-4945 Cancer Casein kinase 2 Kinase inhibitors Silmitasertib

Journal

Advances in protein chemistry and structural biology
ISSN: 1876-1631
Titre abrégé: Adv Protein Chem Struct Biol
Pays: Netherlands
ID NLM: 101497281

Informations de publication

Date de publication:
2021
Historique:
entrez: 26 2 2021
pubmed: 27 2 2021
medline: 6 5 2021
Statut: ppublish

Résumé

CK2 is a constitutively active Ser/Thr protein kinase which phosphorylates hundreds of substrates. Since they are primarily related to survival and proliferation pathways, the best-known pathological roles of CK2 are in cancer, where its targeting is currently being considered as a possible therapy. However, CK2 activity has been found instrumental in many other human pathologies, and its inhibition will expectably be extended to different purposes in the near future. Here, after a description of CK2 features and implications in diseases, we analyze the different inhibitors and strategies available to target CK2, and update the results so far obtained by their in vivo application.

Identifiants

DOI: 10.1016/bs.apcsb.2020.09.003 PMID: 33632467
pubmed: 33632467
pii: S1876-1623(20)30064-X
doi: 10.1016/bs.apcsb.2020.09.003
pii:
doi:

Substances chimiques

Neoplasm Proteins 0
Protein Kinase Inhibitors 0
Casein Kinase II EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-46

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Christian Borgo (C)

Department of Biomedical Sciences, University of Padova, Padova, Italy.

Maria Ruzzene (M)

Department of Biomedical Sciences, University of Padova, Padova, Italy; CNR Neuroscience Institute, Padova, Italy. Electronic address: maria.ruzzene@unipd.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Casein Kinases › Casein Kinase II › Protein kinase CK2 inhibition as a...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Protein kinase CK2 inhibition as a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Protein kinase CK2 inhibition as a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protein kinase CK2 inhibition as a...
questionsmedicales.fr › Tumeurs › Protein kinase CK2 inhibition as a...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Protein kinase CK2 inhibition as a...